An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
The purpose of this study is to compare the effects, good and/or bad, of AGS-003, the study drug, plus regular treatment against regular treatment alone on kidney cancer to find out which is better.
*Must be 18 years or older
* Subjects must have a confirmed diagnosis of kidney cancer
*Will have or have scheduled surgery to remove your kidney cancer
* Subject must not have prior anti-cancer treatment expect for a planned full or partial surgical removal of the affected kidney(s).
* Subject's medical history will be reviewed in detail for study eligibility.
18 - 100
Healthy Volunteers Needed
Duration of Participation
At least 3 years
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Argos Therapeutics, Inc